Insmed Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Bridgewater, n.j. , april 5, 2024 /prnewswire/ -- insmed incorporated (nasdaq: insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to seven new employees.

—additional data from arise study evaluating the impact of arikayce on microbiologic outcomes in patients with newly diagnosed or recurrent mac lung disease to be presented as late-breaker— —data to be presented from arise examining change in patient-reported respiratory symptoms— bridgewater, n.j. , march 27, 2024 /prnewswire/ -- insmed incorporated (nasdaq: insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will present nine abstracts from across its respiratory portfolio at the american thoracic society (ats) 2024 international conference, taking place may 17-22, 2024, in san diego.

Bridgewater, n.j. , march 5, 2024 /prnewswire/ -- insmed incorporated (nasdaq: insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 24 new employees.

Bridgewater, n.j. , feb. 29, 2024 /prnewswire/ -- insmed incorporated (nasdaq:insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor conferences: the td cowen 44th annual health care conference in boston on monday, march 4, 2024, at 2:50 p.m.

—topline data from the phase 3 aspen trial of brensocatib in adult patients with bronchiectasis remain on track to read out in the latter part of second-quarter 2024— —enrollment in the phase 2 study of tpip in patients with ph-ild completed in november 2023; topline data expected in second-quarter 2024 ahead of the aspen readout— —company ends 2023 with $780 million of cash, cash equivalents, and marketable securities, providing runway beyond the expected aspen readout— — arikayce® (amikacin liposome inhalation suspension) total revenue of $83.7 million for fourth-quarter and $305.2 million for full-year 2023, reflecting 24% annual growth and exceeding the upper end of full-year 2023 guidance range— —company reiterates sales guidance for 2024 global arikayce revenues in the range of $340 million to $360 million, reflecting double-digit growth compared to 2023— bridgewater, n...

Insmed (INSM) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.20 per share a year ago.

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insmed (INSM) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $1.09 per share a year ago.

Insmed is looking to broaden the use of its only approved therapy, Arikayce. The company had a record $72 million in revenue in the second quarter.

Insmed's (INSM) shares rise on positive data from the late-stage ARISE study evaluating Arikayce for newly infected lung disease caused by MAC.

Insmed Incorporated (NASDAQ:INSM) shares jumped 18% to $26.62 after the biopharmaceutical company revealed that nearly 44% of patients with nontuberculous mycobacterial (NTM) lung infection in its Phase 3 ARISE study saw an improvement in respiratory symptoms after receiving its Arikayce antibiotic treatment compared with about 33% who received a placebo.   Insmed also noted that more Arikayce-treated patients tested negative for the bacteria after seven months of treatment than did the placebo recipients.

Insmed reported positive top-line results from a late-stage study of its antibiotic drug Arikayce. The data could improve the likelihood of success in another late-stage study of Arikayce.

Insmed Incorporated (NASDAQ:INSM ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Bryan Dunn - Head, IR William Lewis - Chair & CEO Sara Bonstein - CFO Martina Flammer - Chief Medical Officer Conference Call Participants Judah Frommer - Credit Suisse Vamil Divan - Guggenheim Jennifer Kim - Cantor Fitzgerald Leon Wang - Barclays Jason Zemansky - Bank of America Stephen Willey - Stifel Liisa Bayko - Evercore Andrea Tan - Goldman Sachs Joseph Schwartz - Leerink Partners Operator Thank you for standing by. My name is Enrique, and I'll be your conference operator today.

Deep Track Capital, LP (Trades, Portfolio), a prominent investment firm, recently made a significant move in the stock market by acquiring a new stake in Terns Pharmaceuticals Inc. This article will delve into the details of this transaction, provide an overview of both the guru and the traded company, and analyze the potential implications of this move for value investors.

BRIDGEWATER, N.J. , June 7, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA, on Wednesday, June 14, 2023 at 1:20 p.m.